Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2

Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ)...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 4; pp. 808 - 813
Main Authors Comte, Denis, Karampetsou, Maria P., Kis‐Toth, Katalin, Yoshida, Nobuya, Bradley, Sean J., Kyttaris, Vasileios C., Tsokos, George C.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.04.2017
Subjects
Online AccessGet full text
ISSN2326-5191
2326-5205
2326-5205
DOI10.1002/art.40014

Cover

Abstract Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2. Methods Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution. Results Production of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects. Conclusion These data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered.
AbstractList ObjectiveImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2.MethodsCytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution.ResultsProduction of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects.ConclusionThese data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered.
Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon- gamma (IFN gamma ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2. Methods Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution. Results Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFN gamma , IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects. Conclusion These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2. Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution. Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects. These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2.OBJECTIVEImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2.Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution.METHODSCytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution.Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects.RESULTSProduction of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects.These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.CONCLUSIONThese data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.
Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2. Methods Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution. Results Production of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects. Conclusion These data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered.
Author Comte, Denis
Tsokos, George C.
Kis‐Toth, Katalin
Karampetsou, Maria P.
Kyttaris, Vasileios C.
Yoshida, Nobuya
Bradley, Sean J.
Author_xml – sequence: 1
  givenname: Denis
  surname: Comte
  fullname: Comte, Denis
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, and Centre Hospitalier Universitaire Vaudois
– sequence: 2
  givenname: Maria P.
  surname: Karampetsou
  fullname: Karampetsou, Maria P.
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
– sequence: 3
  givenname: Katalin
  surname: Kis‐Toth
  fullname: Kis‐Toth, Katalin
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
– sequence: 4
  givenname: Nobuya
  surname: Yoshida
  fullname: Yoshida, Nobuya
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
– sequence: 5
  givenname: Sean J.
  surname: Bradley
  fullname: Bradley, Sean J.
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
– sequence: 6
  givenname: Vasileios C.
  surname: Kyttaris
  fullname: Kyttaris, Vasileios C.
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
– sequence: 7
  givenname: George C.
  surname: Tsokos
  fullname: Tsokos, George C.
  email: gtsokos@bidmc.harvard.edu
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27992687$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAQxyNUREvpgRdAlrjwoW39Eccxt7JsodJKVMsijpHXnlCXxA62Q8mNR-AZeRJctuVQiQpfxqP5zYz-_3lY7DjvoCgeE3xIMKZHKqTDEmNS3iv2KKPVjFPMd27-RJLd4iDGC5yfFLjC_EGxS4WUtKrFXvHtdbDQohUMPqRXaP6mfInWaA5dF9FJ8D06U8mCSxF9sukcfZhigt5qtByHMaJFmNI59Cr5mLMVxME7g868D92EkkeL7_4zOJ9rpy5B6GD8Yt2vHz_po-J-q7oIB9dxv_h4sljP382W79-ezo-XM80kLmfMGM2ralODaUVFCRgtSq0NN4bUtTZYmw2Rim0k0QK3pMLAFC5ZKcqWcEzYfvFiO3d0g5ouVdc1Q7C9ClNDcHPlX5P9a_74l-FnW3gI_usIMTW9jTpboRxkDU1eWUvBGZf_gXJCJeO1yOjTW-iFH4PLqhtKJa5Kyas7qbyWiJpJdkU9uabGTQ_mr5abe2bg-RbQwccYoL1T7tEtVtuUr-1dCsp2d3Vc2g6mf49ujlfrbcdvZLXONQ
CitedBy_id crossref_primary_10_1136_annrheumdis_2018_214229
crossref_primary_10_1007_s00103_020_03230_8
crossref_primary_10_1111_1440_1681_12946
crossref_primary_10_1097_BOR_0000000000000924
crossref_primary_10_3389_fimmu_2021_632383
crossref_primary_10_1089_jir_2018_0016
crossref_primary_10_2139_ssrn_3802857
crossref_primary_10_3389_fimmu_2018_01088
crossref_primary_10_1038_s41590_020_0677_6
crossref_primary_10_1016_j_clim_2022_109201
crossref_primary_10_3389_fimmu_2022_1016427
crossref_primary_10_1016_j_jaut_2019_102376
crossref_primary_10_4103_jpgm_JPGM_1270_20
crossref_primary_10_1007_s00281_019_00741_8
crossref_primary_10_1038_nrneph_2017_34
crossref_primary_10_1080_08916934_2019_1693545
crossref_primary_10_1038_s41392_023_01350_6
crossref_primary_10_1038_s41467_020_19918_z
crossref_primary_10_1016_j_clim_2018_11_002
crossref_primary_10_3389_fimmu_2022_1075813
crossref_primary_10_1007_s11926_018_0745_1
crossref_primary_10_1016_j_clim_2018_11_001
crossref_primary_10_23868_202110003
crossref_primary_10_3389_fimmu_2023_1305590
crossref_primary_10_4103_injr_injr_48_22
crossref_primary_10_3389_fimmu_2021_667342
crossref_primary_10_1038_s41584_021_00707_x
crossref_primary_10_3390_biomedicines8120559
crossref_primary_10_1016_j_molmed_2022_04_010
crossref_primary_10_1038_nrd_2018_148
crossref_primary_10_1136_ard_2022_222501
crossref_primary_10_1016_j_berh_2017_09_007
crossref_primary_10_1177_0961203318760993
crossref_primary_10_1097_BOR_0000000000000575
crossref_primary_10_1177_0961203317722848
crossref_primary_10_1016_j_clim_2018_08_013
crossref_primary_10_1016_j_jaci_2023_12_023
crossref_primary_10_1097_BOR_0000000000000772
crossref_primary_10_1016_j_clim_2017_06_004
crossref_primary_10_1016_j_coi_2019_07_003
crossref_primary_10_1016_j_jaci_2018_10_015
crossref_primary_10_1080_25785826_2019_1628466
crossref_primary_10_2174_1871530323666230915112642
crossref_primary_10_3389_fimmu_2022_938556
Cites_doi 10.1177/0961203314556139
10.1038/nm.4148
10.1136/annrheumdis-2014-206506
10.1056/NEJMra1100359
10.1136/annrheumdis-2015-207776
10.1155/2011/432595
10.1002/art.1780350606
10.1073/pnas.1605081113
10.1089/jir.2011.0029
10.1007/s10875-008-9235-y
10.1002/art.1780251101
10.1002/cyto.a.21015
10.1016/j.immuni.2013.01.004
10.1038/sj.embor.7401099
10.1038/44385
ContentType Journal Article
Copyright 2016, American College of Rheumatology
2016, American College of Rheumatology.
2017, American College of Rheumatology
Copyright_xml – notice: 2016, American College of Rheumatology
– notice: 2016, American College of Rheumatology.
– notice: 2017, American College of Rheumatology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
ADTOC
UNPAY
DOI 10.1002/art.40014
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Toxicology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic

Toxicology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2326-5205
EndPage 813
ExternalDocumentID 10.1002/art.40014
4321261035
27992687
10_1002_art_40014
ART40014
Genre shortCommunication
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIH
  funderid: P01‐AI‐065687, R01‐AI‐42269, and R37‐AI‐49954
– fundername: SICPA Foundation
– fundername: NIAID NIH HHS
  grantid: R01 AI042269
– fundername: NIAID NIH HHS
  grantid: P01 AI065687
– fundername: NIAID NIH HHS
  grantid: R37 AI049954
GroupedDBID 0R~
1OC
33P
3SF
4.4
52O
52U
52V
53G
5VS
AAESR
AAEVG
AAFWJ
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
DCZOG
DIK
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
FUBAC
G-S
G.N
GODZA
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
NF~
O66
O9-
OVD
P2W
PQQKQ
QB0
ROL
SUPJJ
TEORI
V9Y
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WVDHM
WXSBR
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c3904-3ddc566b8edf7621edc74ccd5dd188cd0cdb19a3b91c70f160e3a043474f15013
IEDL.DBID UNPAY
ISSN 2326-5191
2326-5205
IngestDate Wed Oct 01 15:24:46 EDT 2025
Wed Oct 01 15:07:14 EDT 2025
Fri Jul 11 05:15:37 EDT 2025
Fri Jul 25 12:07:15 EDT 2025
Sun Jul 13 05:37:41 EDT 2025
Mon Jul 21 06:05:22 EDT 2025
Wed Oct 01 01:39:43 EDT 2025
Thu Apr 24 23:09:43 EDT 2025
Sun Sep 21 06:14:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2016, American College of Rheumatology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3904-3ddc566b8edf7621edc74ccd5dd188cd0cdb19a3b91c70f160e3a043474f15013
Notes Drs. Comte and Karampetsou contributed equally to this work.
Supported by the NIH (grants P01‐AI‐065687, R01‐AI‐42269, and R37‐AI‐49954 to Dr. Tsokos) and the SICPA Foundation (grant to Dr. Comte).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40014
PMID 27992687
PQID 1881783937
PQPubID 946334
PageCount 6
ParticipantIDs unpaywall_primary_10_1002_art_40014
proquest_miscellaneous_1888975359
proquest_miscellaneous_1851293587
proquest_journals_2290649567
proquest_journals_1881783937
pubmed_primary_27992687
crossref_primary_10_1002_art_40014
crossref_citationtrail_10_1002_art_40014
wiley_primary_10_1002_art_40014_ART40014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2017
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: April 2017
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheumatol
PublicationYear 2017
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 24
2011; 2011
1982; 25
2013; 38
2010
2015; 74
2008; 28
2007; 8
2011; 31
2016; 113
2016; 75
1992; 35
2011; 79
1999; 401
2011; 365
2016; 22
e_1_2_6_10_1
Lieberman LA (e_1_2_6_7_1) 2010
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_6_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_3_1
e_1_2_6_11_1
e_1_2_6_2_1
e_1_2_6_12_1
e_1_2_6_17_1
e_1_2_6_15_1
e_1_2_6_16_1
22129255 - N Engl J Med. 2011 Dec 1;365(22):2110-21
21265010 - Cytometry A. 2011 Feb;79(2):167-74
18059313 - EMBO Rep. 2007 Dec;8(12):1142-8
20625413 - J Biomed Biotechnol. 2010;2010:740619
10537110 - Nature. 1999 Oct 14;401(6754):708-12
25609413 - Ann Rheum Dis. 2015 Apr;74(4):791-2
18726679 - J Clin Immunol. 2008 Nov;28(6):635-9
22028588 - J Biomed Biotechnol. 2011;2011:432595
27482100 - Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9321-6
26324847 - Ann Rheum Dis. 2016 Jul;75(7):1407-15
25801878 - Lupus. 2015 Apr;24(4-5):351-63
23352221 - Immunity. 2013 Jan 24;38(1):13-25
21877904 - J Interferon Cytokine Res. 2011 Oct;31(10):769-79
27500725 - Nat Med. 2016 Sep;22(9):991-3
7138600 - Arthritis Rheum. 1982 Nov;25(11):1271-7
References_xml – volume: 401
  start-page: 708
  year: 1999
  end-page: 12
  article-title: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
  publication-title: Nature
– volume: 74
  start-page: 791
  year: 2015
  end-page: 2
  article-title: Rapid induction of clinical remission by low‐dose interleukin‐2 in a patient with refractory SLE
  publication-title: Ann Rheum Dis
– volume: 2011
  start-page: 432595
  year: 2011
  article-title: Inflammatory cytokines in systemic lupus erythematosus
  publication-title: J Biomed Biotechnol
– start-page: 740619
  year: 2010
  article-title: The IL‐2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity
  publication-title: J Biomed Biotechnol
– volume: 75
  start-page: 1407
  year: 2016
  end-page: 15
  article-title: Low‐dose interleukin‐2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
  publication-title: Ann Rheum Dis
– volume: 25
  start-page: 1271
  year: 1982
  end-page: 7
  article-title: The 1982 revised criteria for the classification of systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 35
  start-page: 630
  year: 1992
  end-page: 40
  article-title: and the Committee on the Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients
  publication-title: Arthritis Rheum
– volume: 365
  start-page: 2110
  year: 2011
  end-page: 21
  article-title: Systemic lupus erythematosus
  publication-title: N Engl J Med
– volume: 28
  start-page: 635
  year: 2008
  end-page: 9
  article-title: IL‐2 family of cytokines in T regulatory cell development and homeostasis
  publication-title: J Clin Immunol
– volume: 31
  start-page: 769
  year: 2011
  end-page: 79
  article-title: The dysregulation of cytokine networks in systemic lupus erythematosus
  publication-title: J Interferon Cytokine Res
– volume: 79
  start-page: 167
  year: 2011
  end-page: 74
  article-title: SPICE: exploration and analysis of post‐cytometric complex multivariate datasets
  publication-title: Cytometry A
– volume: 113
  start-page: 9321
  year: 2016
  end-page: 6
  article-title: Engagement of SLAMF3 enhances CD4 T‐cell sensitivity to IL‐2 and favors regulatory T‐cell polarization in systemic lupus erythematosus
  publication-title: Proc Natl Acad Sci U S A
– volume: 22
  start-page: 991
  year: 2016
  end-page: 3
  article-title: Low‐dose interleukin‐2 treatment selectively modulates CD4 T cell subsets in patients with systemic lupus erythematosus
  publication-title: Nat Med
– volume: 8
  start-page: 1142
  year: 2007
  end-page: 8
  article-title: Interleukin 2: from immunostimulation to immunoregulation and back again
  publication-title: EMBO Rep
– volume: 24
  start-page: 351
  year: 2015
  end-page: 63
  article-title: T cells as a therapeutic target in SLE
  publication-title: Lupus
– volume: 38
  start-page: 13
  year: 2013
  end-page: 25
  article-title: Interleukin‐2 at the crossroads of effector responses, tolerance, and immunotherapy
  publication-title: Immunity
– ident: e_1_2_6_3_1
  doi: 10.1177/0961203314556139
– ident: e_1_2_6_8_1
  doi: 10.1038/nm.4148
– ident: e_1_2_6_9_1
  doi: 10.1136/annrheumdis-2014-206506
– start-page: 740619
  year: 2010
  ident: e_1_2_6_7_1
  article-title: The IL‐2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity
  publication-title: J Biomed Biotechnol
– ident: e_1_2_6_2_1
  doi: 10.1056/NEJMra1100359
– ident: e_1_2_6_10_1
  doi: 10.1136/annrheumdis-2015-207776
– ident: e_1_2_6_11_1
  doi: 10.1155/2011/432595
– ident: e_1_2_6_14_1
  doi: 10.1002/art.1780350606
– ident: e_1_2_6_17_1
  doi: 10.1073/pnas.1605081113
– ident: e_1_2_6_12_1
  doi: 10.1089/jir.2011.0029
– ident: e_1_2_6_5_1
  doi: 10.1007/s10875-008-9235-y
– ident: e_1_2_6_13_1
  doi: 10.1002/art.1780251101
– ident: e_1_2_6_15_1
  doi: 10.1002/cyto.a.21015
– ident: e_1_2_6_6_1
  doi: 10.1016/j.immuni.2013.01.004
– ident: e_1_2_6_4_1
  doi: 10.1038/sj.embor.7401099
– ident: e_1_2_6_16_1
  doi: 10.1038/44385
– reference: 18726679 - J Clin Immunol. 2008 Nov;28(6):635-9
– reference: 10537110 - Nature. 1999 Oct 14;401(6754):708-12
– reference: 22028588 - J Biomed Biotechnol. 2011;2011:432595
– reference: 25609413 - Ann Rheum Dis. 2015 Apr;74(4):791-2
– reference: 22129255 - N Engl J Med. 2011 Dec 1;365(22):2110-21
– reference: 25801878 - Lupus. 2015 Apr;24(4-5):351-63
– reference: 23352221 - Immunity. 2013 Jan 24;38(1):13-25
– reference: 27500725 - Nat Med. 2016 Sep;22(9):991-3
– reference: 21877904 - J Interferon Cytokine Res. 2011 Oct;31(10):769-79
– reference: 26324847 - Ann Rheum Dis. 2016 Jul;75(7):1407-15
– reference: 7138600 - Arthritis Rheum. 1982 Nov;25(11):1271-7
– reference: 21265010 - Cytometry A. 2011 Feb;79(2):167-74
– reference: 27482100 - Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9321-6
– reference: 18059313 - EMBO Rep. 2007 Dec;8(12):1142-8
– reference: 20625413 - J Biomed Biotechnol. 2010;2010:740619
SSID ssj0000970605
Score 2.4332016
Snippet Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to...
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune...
Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to...
ObjectiveImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to...
SourceID unpaywall
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 808
SubjectTerms 12-O-Tetradecanoylphorbol-13-acetate
Acetic acid
CD28 antigen
CD3 antigen
CD4 antigen
CD4-Positive T-Lymphocytes - immunology
Cell differentiation
Cell proliferation
Cells, Cultured
Chronic conditions
Clinical trials
Cytokines
Dilution
Humans
Interferon
Interferon-gamma - biosynthesis
Interleukin-17 - biosynthesis
Interleukin-2 - biosynthesis
Interleukin-2 - therapeutic use
Interleukin-4 - biosynthesis
Interleukins
Ionomycin
Lupus
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - immunology
Lymphocytes
Lymphocytes T
Phosphorylation
Production methods
Signal transduction
Signaling
Stimulation
Systemic lupus erythematosus
γ-Interferon
Title Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.40014
https://www.ncbi.nlm.nih.gov/pubmed/27992687
https://www.proquest.com/docview/1881783937
https://www.proquest.com/docview/2290649567
https://www.proquest.com/docview/1851293587
https://www.proquest.com/docview/1888975359
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40014
UnpaywallVersion publishedVersion
Volume 69
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2326-5205
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0000970605
  issn: 2326-5205
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagk7g8cL8UxmQuD5NQSnyJk_A2Sqtx2VShVYynkNiOqBaSqk2A8sRP4DfySzi204jBmJB4c-Rjy3bOsb_jY39G6BGRLBWK5F6QcuFxBX5KGubUYxKwMzhvTGqz37G3L3an_OVhcNi-c2ruwjh-iG7DzViGna-Ngc9V7ub5NrpPn8DoDrhB-WfRhjARph7amO5Pdt7ZJ-Wo8ACfkC5N_WDNLfRr2eMr0h8w8yI635TzdPU5LYrjCNYuQePL6P268e7kydGgqbOB_Pobr-N_9O4KutTCU7zj9OkqOqPLa-jcXhuAv44-PQPXOscOtj_Fw-f8MT7AQ10USzxeVB_xxPG0LvHbWf0BOz70mcSvm3mzxKPFypHEVkv4emOP5yo8qapFscJ1hUdfKscZi-1GZaGbo1n549t3egNNx6OD4a7XPt3gSRabWItSEoBiFmmVw3RLtJIhl1IFSpEoksqXKiNxyrKYyNDPifA1S33OeMhzgKiE3US9sir1bYQjmgVCAwyNpeQyyNJcxJqKMJOSRXnG-mh7_fsS2fKam-c1isQxMtMExjGx49hHDzrRuSPzOEloc60DSWvPywQaTcLIkAeemG1J842rCdn3u2wwVBN9SUsNAwdVWGwVRKfKRJG56RzEfXTLqV_XUBrGMRWm9MNOH0_rxbZVr79LJOAw2cSdf6rwLrpADaKxh5Y2Ua9eNPoe4LE62wJP5MWrrdbyfgLJ8jS0
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagk2A8cB8UBjKXh0koJb7ESXgbpdWE2FShVWxPIbEdUS0kVZsA5YmfwG_kl3BspxGDMSHx5sjHlu2cY3_Hx_6M0FMiWSoUyb0g5cLjCvyUNMypxyRgZ3DemNRmv2P_QOxN-euj4Kh959TchXH8EN2Gm7EMO18bA5-r3M3zbXSfPofRHXCD8i-iDWEiTD20MT2Y7B7bJ-Wo8ACfkC5N_WDNLfRr2dMr0h8w8wq63JTzdPU5LYrTCNYuQeNr6P268e7kycmgqbOB_Pobr-N_9O46utrCU7zr9OkGuqDLm-jSfhuAv4U-vQTXOscOtr_Aw1f8GT7EQ10USzxeVB_xxPG0LvG7Wf0BOz70mcRvmnmzxKPFypHEVkv4emuP5yo8qapFscJ1hUdfKscZi-1GZaGbk1n549t3ehtNx6PD4Z7XPt3gSRabWItSEoBiFmmVw3RLtJIhl1IFSpEoksqXKiNxyrKYyNDPifA1S33OeMhzgKiEbaFeWZX6LsIRzQKhAYbGUnIZZGkuYk1FmEnJojxjfbSz_n2JbHnNzfMaReIYmWkC45jYceyjx53o3JF5nCW0vdaBpLXnZQKNJmFkyAPPzLak-cbVhOxHXTYYqom-pKWGgYMqLLYKonNlosjcdA7iPrrj1K9rKA3jmApT-kmnj-f1Yseq198lEnCYbOLeP1V4H21Sg2jsoaVt1KsXjX4AeKzOHrY29xOTcDO7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brief+Report%3A+CD4%2B+T+Cells+From+Patients+With+Systemic+Lupus+Erythematosus+Respond+Poorly+to+Exogenous+Interleukin-2&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Comte%2C+Denis&rft.au=Karampetsou%2C+Maria+P&rft.au=Kis-Toth%2C+Katalin&rft.au=Yoshida%2C+Nobuya&rft.date=2017-04-01&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=69&rft.issue=4&rft.spage=808&rft.epage=813&rft_id=info:doi/10.1002%2Fart.40014&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon